172 related articles for article (PubMed ID: 36333801)
1. Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer.
Alexandrova E; Lamberti J; Memoli D; Quercia C; Melone V; Rizzo F; Tarallo R; Giurato G; Nassa G; Weisz A
Cancer Cell Int; 2022 Nov; 22(1):336. PubMed ID: 36333801
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
3. The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Salvati A; Gigantino V; Nassa G; Giurato G; Alexandrova E; Rizzo F; Tarallo R; Weisz A
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689915
[TBL] [Abstract][Full Text] [Related]
4. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
5. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
6. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
8. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
Kim MK; Caplen N; Chakka S; Hernandez L; House C; Pongas G; Jordan E; Annunziata CM
BMC Cancer; 2016 Aug; 16(1):678. PubMed ID: 27558154
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of
Lonetti A; Indio V; Laginestra MA; Tarantino G; Chiarini F; Astolfi A; Bertuccio SN; Martelli AM; Locatelli F; Pession A; Masetti R
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698374
[TBL] [Abstract][Full Text] [Related]
10. Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.
Alexandrova E; Salvati A; Pecoraro G; Lamberti J; Melone V; Sellitto A; Rizzo F; Giurato G; Tarallo R; Nassa G; Weisz A
Front Genet; 2022; 13():864612. PubMed ID: 35495127
[TBL] [Abstract][Full Text] [Related]
11. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
12. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
13. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
14. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.
Mao Y; Sun Y; Wu Z; Zheng J; Zhang J; Zeng J; Lee C; Kim JK
Cell Death Dis; 2021 Dec; 12(12):1141. PubMed ID: 34887387
[TBL] [Abstract][Full Text] [Related]
15. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
16. Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Chava S; Bugide S; Edwards YJK; Gupta R
Oncogenesis; 2021 Jul; 10(7):48. PubMed ID: 34253709
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
18. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptomics defines Dot1L interacting partners and downstream target genes in the mouse molar dental pulp.
Guzzo R; Enkhmandakh B; Becker T; Joshi P; Robson P; Vijaykumar A; Mina M; Shin DG; Bayarsaihan D
Int J Dev Biol; 2022; 66(7-8-9):391-400. PubMed ID: 36942693
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
Brzezinka K; Nevedomskaya E; Lesche R; Haegebarth A; Ter Laak A; Fernández-Montalván AE; Eberspaecher U; Werbeck ND; Moenning U; Siegel S; Haendler B; Eheim AL; Stresemann C
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
